US FDA issues 7 Form 483 observations at Cipla Pithampur plant
US FDA inspected Cipla’s Pithampur facility from August 17–25 and issued seven observations in Form 483. The notice suggests potential regulatory noncompliance at the site, which can affect product quality controls and may trigger additional remediation or follow-up inspections, though no broader outcome is specified here.